BiotechTube
Mercy BioAnalytics

Mercy BioAnalytics

Natick, United States· Est.
mercybio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $46M

Overview

Mercy BioAnalytics is a private, pre-revenue diagnostics company pioneering an extracellular vesicle (EV)-based liquid biopsy platform for multi-cancer early detection. Its patented Mercy Halo™ technology uses low-cost qPCR to detect co-localized biomarkers on individual EVs, aiming for high sensitivity and specificity in identifying early-stage cancers. Led by an experienced team with diagnostics industry veterans, including Chairman Stan Lapidus (founder of Exact Sciences), the company is advancing its pipeline, starting with an ovarian cancer screening test, and has established a Medicare coverage pathway strategy. Mercy positions its EV approach as a potentially superior alternative to cell-free DNA (cfDNA) methods for detecting poorly vascularized, early-stage tumors.

Oncology

Technology Platform

Mercy Halo™ platform uses low-cost qPCR to detect co-localized cancer-associated biomarkers on individual extracellular vesicles (EVs/exosomes) from blood samples.

Funding History

2
Total raised:$46M
Series A$41M
Seed$5M

Opportunities

The multi-cancer early detection (MCED) market represents a multi-billion dollar opportunity with immense unmet need.
Mercy's focus on low-cost, qPCR-based EV detection could enable broader accessibility and more favorable reimbursement compared to expensive sequencing-based tests, potentially capturing significant market share in population screening programs.

Risk Factors

Key risks include the clinical failure of its EV-based approach to achieve required sensitivity/specificity in large validation studies, intense competition from well-funded cfDNA-based MCED companies, and the significant regulatory hurdles associated with obtaining FDA approval for a novel cancer screening test in asymptomatic populations.

Competitive Landscape

Mercy competes in the crowded liquid biopsy for early detection space against major players like GRAIL (Guardant Health), Exact Sciences, Freenome, and others primarily using cell-free DNA (cfDNA) and multi-omic approaches. Mercy's differentiation is its exclusive focus on extracellular vesicles, arguing they are more abundant than cfDNA in early-stage cancer, and its use of low-cost qPCR technology.

More companies in Diagnostics & Precision Medicine →More companies in United States →